Biopharma Market Size, Share and Global Industry Report 2027

Biopharma Market
Analysis 2020
Report Crux Market Research
Kemp House 152 – 160 City Road London EC1V
2NX
+91 895 615 7215
sales@reportcrux.com
https://www.reportcrux.com/
Date: July 2020
_________________

ReportCrux Market Research
Biopharma Market - Global
Industry Analysis, Size, Share,
Forecast 2016 – 2027
Single User License: USD 2999
• Flat 20% Discount!!
• Free Customization as per your requirement
• You will get Custom Report at Syndicated Report price
• Report will be delivered within 10-15working days
ReportCrux Market Research
Kemp House 152 – 160 City Road London EC1V
2NX
https://www.reportcrux.com/
sales@reportcrux.com
View our Analysis
Request Sample Report
Request Customization
Report
Buy Now

Report Description
Report Crux Market Research has published a new report titled "Biopharma Market by Product (Monoclonal Antibodies [ Anti-Cancer Monoclonal
Antibodies, Anti Inflammatory Monoclonal Antibodies, and Other Monoclonal Antibodies], Purified Proteins [Leukemia Inhibitory Factor (LIF), P53
Protein, P38 Protein, and Other Purified Proteins], Recombinant Proteins [Serum Albumin, Amyloid Protein, Defensin, and Transferrin], Vaccines
[Recombinant Vaccines, Conventional Vaccines, and Recombinant Enzymes], Recombinant Growth Factors [Erythropoietin, and Granulocyte
Colony Stimulating Factors], Recombinant Hormones [Recombinant Human Growth Hormones, Recombinant Insulin, and Other Recombinant
Hormones], and Other Product Types); by Therapeutic Application (Oncology, Inflammatory and Infectious Diseases, Neurological Diseases,
Infectious Diseases, Cardiovascular Diseases, Metabolic Disorders, Hormonal Disorders, and Other Diseases); and by Region: Global Industry
Trends, Dynamics, Competitive Insights and Forecast Analysis, 2020 – 2027”.
Biopharmaceuticals are produced by living organisms, such as microorganisms and animal cells, and have a high therapeutic value. Most
biopharmaceuticals are life-form pharmaceutical products, genetically modified from plants and animals and are classified as transgenic organisms,
and this process is used to generate biopharmaceuticals. These massive and complex molecular drugs are often referred to as biologics or biotech
drugs. Recombinant human insulin was one of the first substances to be licensed for medical purposes, and there are currently almost 300
biopharmaceutical drugs that have been licensed and are available on the market.
The global demand for biopharmaceuticals is driven by a number of factors like increase in the elderly population, an increase in the prevalence of
chronic diseases like cancer and diabetes, and an increase in the global acceptance of biopharmaceuticals. In addition, an increase in strategic
partnerships between biopharmaceutical companies is also expected to complement the growth of the biopharmaceuticals industry. Furthermore,
clearance for newer biopharmaceutical products and continuous R&D is also expected to improve this market positively. However, the high costs
of these medications are one of the main constraints on this industry and, in order to make them economically viable, the cost needs to be
reduced greatly.
Biopharma Market Size
Biopharma market was valued at approximately USD 244.1 Billion in 2019 and is expected to generate revenue of around USD 546.6 Billion by end
of 2027, growing at a CAGR of around 10.6% between 2020 and 2027

Segmentation Analysis
The global market for the biopharma is segmented into product, therapeutic area, application, and region.
By Product
Based on product, the market is for biopharma is segmented into recombinant growth factors, monoclonal antibodies, recombinant proteins,
vaccines, purified proteins, recombinant hormones, and other product types. The monoclonal antibodies market is further divided into antiinflammatory
monoclonal antibodies, anti-cancer monoclonal antibodies, and other monoclonal antibodies. The purified proteins market is further
bifurcated into P38 protein, leukemia inhibitory factor, P53 protein, and other purified proteins. The recombinant proteins market is further
divided into serum albumin, defensin, amyloid protein, and transferrin. Vaccines are further divided into conventional vaccines, recombinant

vaccines, and recombinant enzymes. The recombinant growth factors are further divided into granulocyte colony stimulating factors, and
erythropoietin. The recombinant hormones market is further divided into recombinant human growth hormones, recombinant insulin, and other
recombinant hormones. The market for monoclonal antibodies held almost 28% share of the market in 2019. Monoclonal antibodies are used in
cancer treatment areas. Their usage is becoming increasingly widespread in developed countries like the U.S. and the U.K. Contrary, the
recombinant proteins segment is expected to show rapid growth over the forecast period.
By Therapeutic Application
Based on therapeutic application, the market is categorized into oncology, inflammatory and infectious diseases, neurological diseases, infectious
diseases, cardiovascular diseases, metabolic disorders, hormonal disorders, and other diseases. The oncology segment held almost 25% share of
the market in 2019. According to the International Agency for Cancer Research (IARC), there were almost 18 million new cases of cancer and 10
million deaths in 2018. In fact, the United Nations Program on HIV and AIDS (UNAIDS) estimated that 37 million people were living with HIV in
2017. Such disquieting statistics has raised an urgent need to change the situation by innovating new and successful medicines that can cure such
deadly diseases consequently raising the number of deaths. Apparently, biopharmaceutical drugs are considered to be effective in curing these
chronic diseases rather than merely treating the same symptoms.
Regional Analysis
Regionally, the market is divided into Asia Pacific, Europe, Latin America, North America, and Middle East & Africa. North America held almost 37%
in 2019 due to the presence of sophisticated healthcare facilities, increasing geriatric population base, and increased healthcare expenditure in the
country. Asia Pacific is likely to grow at high CAGR in the forecast period. Increased investment in R&D, increased acceptance and availability of
biopharmaceuticals for disease treatment and increased understanding of disease diagnosis are some of the factors of market growth in this
region. Moreover, this area offers tremendous prospects for venture capitalists and investors as developed markets are largely saturated.
Key Players Analysis
Major players in biopharma market are Novo Nordisk A/S (Denmark), Johnson & Johnson (U.S.), Pfizer, Inc., (U.S.), Hoffmann-La Roche
(Switzerland), Eli Lilly and Company, Ltd. (U.K.), Biogen, Inc. (U.S.), Merck & Co., Inc. (U.S.), Sanofi (France), Bristol Myers Squibb Company (U.S.),
and Bayer AG (Germany) among others.
The study is a source of reliable data on:
• Market segments and sub-segments
• Market trends and dynamics

• Supply and demand
• Market size
• Current trends/opportunities/challenges
• Competitive landscape
• Technological breakthroughs
• Value chain and stakeholder analysis
The regional analysis covers:
• North America (U.S. and Canada)
• Latin America (Mexico, Brazil, Peru, Chile, and others)
• Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
• Eastern Europe (Poland and Russia)
• Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
• Middle East and Africa (GCC, Southern Africa, and North Africa
Highlights of the report:
• A complete backdrop analysis, which includes an assessment of the parent market
• Important changes in market dynamics
• Market segmentation up to the second or third level
• Historical, current, and projected size of the market from the standpoint of both value and volume
• Reporting and evaluation of recent industry developments
• Market shares and strategies of key players
• Emerging niche segments and regional markets
• An objective assessment of the trajectory of the market Recommendations to companies for strengthening their foothold in the market.
About Us
Report Crux is a global market intelligence aggregator and publisher of market research reports, business information reports, economic and
equity reports. We cater a diverse range of industrial sectors along with niche domains and sub-domains within the industry. We offer exclusive

blend of cutting-edge market insights for the critical business needs. We have an experienced/professional team of researchers, analysts and
consultants that are engaged in gathering and analyzing business information to offer best in class industry report for competitive business needs.
Contact Us:
Scott Mody
Business Development Manger
Report Crux Market Research
Kemp House 152 - 160 City Road London EC1V 2NX
phone Number: +91 895 615 7215 (India)
+1-888-526-5515 (US/Canada)
website: https://www.reportcrux.com/